Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients.

Hypertension is a frequent complication in diabetes, and microalbuminuria has become an essential index of cardiovascular prognosis in type 2 diabetics. The pilot study reported here shows that rilmenidine, in addition to its antihypertensive action and good clinical tolerability, has the further advantage of reducing microalbuminuria, similar to captopril.